Latest news
Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC - AllSciAllSci · Mon, 10 Aug 2026 10:33:20 GMTGenFleet Advances Second Phase III Trial for Oral KRAS G12D Lung Cancer Drug - TipRanksTipRanks · Mon, 10 Aug 2026 00:08:25 GMTGenFleet Therapeutics Schedules Board Meeting to Review Interim Results and Dividend - TipRanksTipRanks · Wed, 05 Aug 2026 22:36:15 GMT